Sutro nets $85.4M; HiFiBiO pens Takeda R&D collaboration

Non-Malignant Disorders

Sutro nets $85.4M; HiFiBiO pens Takeda R&D...

Sutro Biopharma nets $85.4M to drive antibody-drug conjugates Sutro Biopharma reeled in an $85.4 million series E that will advance some early-stage programs as well as its cancer pipeline, which i...

Aug 02, 2018

Delveinsight
Rheumatoid Arthritis...

Rheumatoid Arthritis (RA) is a chronic, inflammatory autoimmune disease that leads to progressive an.....

Find More
Delveinsight
Toll-like receptors (TLR)...

Toll-like receptors (TLR) 7 and 8 are functionally localized to endosomes and recognize specific RNA.....

Find More
Delveinsight
Gene Therapies

Gene therapies are regarded as one of the potential revolution in the Pharmaceutical field and Healt.....

Find More